Jade Biosciences, Inc. Common Stock JBIO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.05M+80.1% | $28.54M-8.6% | $22.01M+62.1% | $22.55M+28,806% | $20.02M-0.3% | ||
| $7.39M+120% | $6.44M+49.6% | $5.39M+290% | $5.23M+922% | $3.36M-25.9% | ||
| $43.45M+85.8% | $34.98M-1.6% | $27.4M+83.1% | $27.78M+4,608% | $23.38M-5.0% | ||
| -$43.45M-85.8% | -$34.98M+1.6% | -$27.4M-83.1% | -$27.78M-4,608% | -$23.38M+5.0% | ||
| $3.09M+121% | —— | $2.23M+270% | -$4.36M— | -$14.79M-1,132% | ||
| -$40.35M-5.7% | —— | —— | —— | -$38.17M— | ||
| $16K+10.3% | $14.5K— | $14.5K— | $14.5K— | $14.5K— | ||
| -$40.37M-5.8% | -$31.93M+32.0% | -$25.18M-54.7% | -$32.13M-5,346% | -$38.17M-64.6% | ||
| -$0.57+95.3% | -$0.11+99.3% | -$0.48+90.7% | -$0.86-353% | -$12.10-1,358% | ||
| -$43.44M-85.8% | -$34.97M+1.6% | -$27.39M-85.7% | -$27.78M-4,843% | -$23.38M+4.9% | ||
| -$43.45M-85.8% | -$34.98M+1.6% | -$27.4M-83.1% | -$27.78M-4,608% | -$23.38M+5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Jade Biosciences, Inc. Common Stock profitable?
- Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's earnings per share?
- Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
- Where does Jade Biosciences, Inc. Common Stock's income statement data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.